An open-label, multicenter, phase 1b/2 study of navtemadlin (KRT-232) in patients with relapsed/refractory acute myeloid leukemia secondary to myeloproliferative neoplasms.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Raajit Rampal, Sundra Ramanathan, Cristina Papayannidis, Nikolas von Bubnoff, Maria del Mar Tormo Díaz, Maria Belen Vidriales, Adolfo de la Fuente Burguera, Lucia Masarova, Haifa Kathrin Al-Ali, David Lavie, Sandrine Niyongere, Tiffanie Chan, Jesse S. McGreivy, Wayne P. Rothbaum, Alice S. Mims, Thomas Cluzeau
Institutions: Memorial Sloan Kettering Cancer Center, Istituto di Ematologia di Bologna, University Hospital Schleswig-Holstein, University of Lübeck, Hospital Clínico Universitario de Valencia, MD Anderson Cancer Center Madrid, The University of Texas MD Anderson Cancer Center, University Hospital in Halle, Hadassah Medical Center, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Kartos Therapeutics, Inc. (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Centre Hospitalier Universitaire de Nice
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286298973